A61P 5 - Drugs for disorders of the endocrine system

Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
12/2004
12/08/2004	CN1553917A 17alpha-hydroxy-14beta-steroids with hormonal effect
12/08/2004	CN1553810A Use of HCG and LH in controlled ovarian hyperstimulation
12/07/2004	US6828456 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
12/07/2004	US6828440 Analgesics; side effect reduction
12/07/2004	US6828335 Oxazole or thiazole-ethyl-oxy-indane acetic acid derivatives; useful for the treatment of diseases such as diabetes, obesity, hyperlipidemia and atherosclerosis
12/07/2004	US6828305 Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
12/07/2004	US6827931 Method for treating endocrine disorders
12/02/2004	WO2004103995A1 N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
12/02/2004	WO2004103992A1 2-aminoquinoline derivative
12/02/2004	WO2004103941A2 Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents
12/02/2004	WO2004078947A3 Use of thyroid-stimulating hormone to induce lipolysis
12/02/2004	US20040243606 Hormonal contraceptive product
12/02/2004	US20040242842 Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use
12/02/2004	US20040242675 Compositions useful for the treatment of pathologies responding to the activation of PPAR-gamma receptor
12/02/2004	US20040242647 Use of organic compounds
12/02/2004	US20040242575 for use with various disorders including sleep disorders; depression; cardiovascular disorders; pain; neurodegenerative disorders; psychiatric disorders etc.
12/02/2004	US20040242564 1,2,3,4-tetrahydroisoquinolines derivatives
12/02/2004	US20040242551 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
12/02/2004	US20040242487 Identifying a subject in need of inhibiting appetite or weight gain and administering an effective amount of an antagonist of melanocyte concentrating hormone (MCH) to subject, wherein antagonist binds an MCH receptor
12/02/2004	US20040242478 5-cnac as oral delivery agent for parathyroid hormone fragments
12/02/2004	US20040241249 Prepared by ketone extraction of krill; evaporating ketone in liquid product; 2nd extraction of the solids in the product with an alcohol or acetate solvent to form a soluble lipid fraction; separating liquids and solids in 2nd product and evaporating solvent from liquid fraction; recovering solids
12/02/2004	US20040241229 Sustained-release composition and process for producing the same
12/02/2004	US20040241228 Spirolaxine acts as active principle in association with all-trans retinoic acid for treatment of those pathologies responding to activation of PPAR gamma receptor, such as acute malignant haemopathies. and Type 2 insulin-resistant diabetes
12/02/2004	US20040241219 System comprising back layer, protective layer and at least one active-compound-containing polymer matrix comprising a polyacrylate which contains extremely reduced number of functional groups; in one embodiment polyacrylate is free of hydroxyl and/or carboxyl groups
12/02/2004	CA2526374A1 2-aminoquinoline derivatives
12/02/2004	CA2525310A1 Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents
12/02/2004	CA2524936A1 Compositions and methods for the preparation of human growth hormone glycosylation mutants
12/01/2004	EP1481989A1 A-33 related antigens and their pharmacological uses
12/01/2004	EP1481667A1 NEP inhibitors for the treatment of female sexual dysfunction
12/01/2004	EP1481078A2 Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
12/01/2004	EP1480996A1 Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form
12/01/2004	EP1480651A1 Aerosol formulations containing esters of 3,17-dihydroxy oestratriene derivatives for pulmonary delivery
12/01/2004	EP1480634A2 Treating benign prostate hyperplasia with sarms
12/01/2004	EP1480618A1 Sustained release drug formulations containing a carrier peptide
12/01/2004	EP1185539B1 Organosilyl compounds having nuclear hormone receptor modulating activity
12/01/2004	EP1183040B1 Therapeutic use of an inhibitor of a hedgehog signalling pathway
12/01/2004	EP1121449A4 Delivery system for porcine somatotropin
12/01/2004	CN1551919A 治疗性结合分子 Therapeutic binding molecules
12/01/2004	CN1551888A Modified human growth hormone
12/01/2004	CN1551884A Thieno 2,3-d]pyrimidines with combined LH and FSH agonistic activity
12/01/2004	CN1551878A 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
12/01/2004	CN1551789A Single dose aromatase inhibitor for treating infertility
12/01/2004	CN1551766A Lymphocytic activation inhibitor and remedial agent for autoimmune disease
12/01/2004	CN1550233A Skin patch and method for administering testosterone
12/01/2004	CN1177860C Cholenic acid amides and pharmaceutical compositions thereof
12/01/2004	CN1177848C Bicyclic heteroaromatic compounds useful as LH agonists
12/01/2004	CN1177844C Cyclopropanes as CGRP antagonists, medicaments contg. said compounds and method for production thereof
12/01/2004	CN1177828C Novel hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines
12/01/2004	CN1177821C Matrix metalloprotease inhibitors
11/2004
11/30/2004	US6825217 Heterocyclic amines such as 4-(3'-thienyl)-alpha, alpha, 1-trimethyl-4-piperidinemethanol and/or prodrugs, used as analgesics for prophylaxis of neuropathic pain
11/30/2004	US6825193 Heterocyclic amines such as 4-(3,4-dichlorophenyl)-2-(2-(4-methylpiperazin-1-yl)-benzylidene) -thiomorpholin-3-one, used as antiserotonine agents
11/30/2004	CA2298245C Matrix controlled release device
11/25/2004	WO2004101568A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
11/25/2004	WO2004101529A1 Nitrogenous heterocyclic compound and medical use thereof
11/25/2004	WO2004101514A1 Cyanofluoropyrrolidine derivative
11/25/2004	WO2004101483A1 Novel trisubstituted benzene derivative, process for producing the same and medical drug composition containing the derivative
11/25/2004	WO2004100976A1 Klotho protein, anti-klotho protein antibody and use thereof
11/25/2004	WO2004100959A1 External patch containing estrogen and/or progestogen
11/25/2004	WO2004074428A3 Treatment of metabolic disorders
11/25/2004	WO2003103718A3 Intracellular delivery of biological effectors
11/25/2004	US20040236116 Novel bicyclic and tricyclic cannabinoids
11/25/2004	US20040236109 Tetrahydroquinoline derivatives
11/25/2004	US20040236102 Enzyme inhibitor for treating a non-insulin dependent diabetes mellitus; 3-Amino-4-(3,4-difluorophenyl)butanoyl]-4-[2-({3-[(methylsulfonyl)amino]-phenyl}-amino)-2-oxoethyl]piperazin-2-yl}acetic acid
11/25/2004	US20040235950 Administering, topically or systemically, an inhibitor of the matrix degrading enzymes and a cytokine inhibitor that alleviates inflammation and also alleviate neutrophil infiltration
11/25/2004	US20040235938 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
11/25/2004	US20040235924 antidepressants; anxiolytic agents; eating disorders; post-traumatic stress disorders; headaches;drug addition; antiinflammatory agents
11/25/2004	US20040235872 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
11/25/2004	US20040235871 A hexahydro-1,5,6,8-tetraaza-acenaphthylene or -1,3,4-triazaphenalene derivatives; treatment of depression and anxiety; inflammatory bowel disease; treatment of conditions mediated by corticotropin-releasing factor
11/25/2004	US20040235866 Lymphocytic activation inhibitor and remedial agent for autoimmune disease
11/25/2004	US20040235816 Administering compounds such as 1-benzhydryl-3-[(methylsulfonyl)(phenyl)methylene]azetidine for therapy of schizophrenia, Parkinson's disease, and Alzeimer's disease
11/25/2004	US20040235808 Administering compounds such as 17 beta -[4-(dimethylamino)-benzoyloxy]-androst-4-en-3-one for modulating a function mediated by the androgen receptor in a tissue selective manner
11/25/2004	US20040235804 Multiple dose aromatase inhibitor for treating infertility
11/25/2004	US20040235753 Oxytocin agonists
11/25/2004	US20040235752 3-fluoro-pyrrolidines as antidiabetic agents
11/25/2004	US20040235748 Agents for preventing postoperative recurrence of premenopausal breast cancer
11/25/2004	US20040235117 Fusion protein comprised of t umor necrosis factor, cartilage oligomeric and cartliage matrix protein domains for use in identifying modulator for treatment of infections, autoimmue, cell proliferative, neurodegenerative and inflammatory diseases
11/25/2004	US20040235006 Chemical compounds
11/25/2004	US20040234626 Food supplement for increasing lean mass and strength
11/25/2004	US20040234578 Bioadhesive, closed-cell foam film, sustained release, delivery devices and methods of making and using same
11/25/2004	US20040234572 Preparation of sustained release pharmaceutical composition
11/25/2004	US20040234544 Formulation containing (lyso-)phosphatidylserine for the prevention and treatment of stress states in warm blooded animals
11/25/2004	US20040234522 therapy, diagnosis of immunology diseases; response to antigenic stimulants; cell differentiation of lymphocytes
11/25/2004	CA2525442A1 Cyanofluoropyrrolidine derivatives
11/24/2004	EP1479684A1 Thienopyrimidines, process for preparing the same and use thereof
11/24/2004	EP1478762A2 Nucleic acid-associated proteins
11/24/2004	EP1478745A2 Kinases and phosphatases
11/24/2004	EP1478624A1 Chemical compounds
11/24/2004	EP1478620A1 Phenethanolamine derivatives for treatment of respiratory diseases
11/24/2004	EP1478613A2 Substituted 10-aryl-11h-benzo[b]fluorenes and 7-aryl-5,6-dihydro-benz[a]anthracenes for selective effects on estrogen receptors
11/24/2004	EP1478369A1 Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases
11/24/2004	EP1478353A1 Sustained release pharmaceutical composition
11/24/2004	EP1478340A1 Pharmaceutical formulation comprising an aqueous suspension of an androstane derivative for the treatment of inflammatory and allergic conditions
11/24/2004	EP1478233A2 Method for administering glp-1 molecules
11/24/2004	EP1313496B1 Use of a composition comprising an extract of pollen for the treatment of edema
11/24/2004	EP1313495B1 Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders
11/24/2004	EP1313493B1 Use of a composition comprising an extract of pollen for the treatment of irritability
11/24/2004	EP1313492B1 Use of a composition comprising an extract of pollen for the treatment of dysphoria
11/24/2004	EP1144673A4 Methods of screening protease inhibitors, of inducing mice susceptible to hiv protease inhibitor-induced dyslipidemia, and genes associated therewith
11/24/2004	EP1109572A4 Neuroprotection
11/24/2004	CN1549826A Compositions and methods of treating diabetes

1 ... 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 ... 290